{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:36:48Z","timestamp":1792816608891,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Grant-in-Aid for Research in Nagoya City University","award":["2514001"],"award-info":[{"award-number":["2514001"]}],"id":[{"id":"https:\/\/ror.org\/04wn7wc95","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"DOI":"10.1007\/s43441-026-01063-2","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T14:45:55Z","timestamp":1792766755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Investigator-Initiated Trials as a Clinical Development Approach for Orphan Drugs Compared with Industry-Sponsored Trials in Japan"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2587-5711","authenticated-orcid":false,"given":"Shingo","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4876-446X","authenticated-orcid":false,"given":"Eiji","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"1063_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/d41573-020-00060-w","volume":"19","author":"A Hechtelt Jonker","year":"2020","unstructured":"Hechtelt Jonker A, Hivert V, Gabaldo M, Batista L, O\u2019Connor D, Aartsma-Rus A, et al. Boosting delivery of rare disease therapies: the IRDiRC orphan drug development guidebook. Nat Rev Drug Discov. 2020;19:495\u20136.","journal-title":"Nat Rev Drug Discov"},{"key":"1063_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104346","volume":"30","author":"JA Katakowski","year":"2025","unstructured":"Katakowski JA, L\u00f3pez JC. Drug development for neglected ultra-rare diseases of no commercial interest: challenges and opportunities. Drug Discov Today. 2025;30:104346.","journal-title":"Drug Discov Today"},{"key":"1063_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nrd.2017.246","volume":"17","author":"KM Boycott","year":"2018","unstructured":"Boycott KM, Ardig\u00f3 D. Addressing challenges in the diagnosis and treatment of rare genetic diseases. Nat Rev Drug Discov. 2018;17:151\u20132.","journal-title":"Nat Rev Drug Discov"},{"key":"1063_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104160","volume":"29","author":"KDS Fernald","year":"2024","unstructured":"Fernald KDS, F\u00f6rster PC, Claassen E, van de Burgwal LHM. The pharmaceutical productivity gap\u2014incremental decline in R&D efficiency despite transient improvements. Drug Discov Today. 2024;29:104160.","journal-title":"Drug Discov Today"},{"key":"1063_CR5","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","volume":"323","author":"OJ Wouters","year":"2020","unstructured":"Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA. 2020;323:844\u201353.","journal-title":"JAMA"},{"key":"1063_CR6","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1182\/blood-2010-09-308858","volume":"117","author":"NA Goldenberg","year":"2011","unstructured":"Goldenberg NA, Spyropoulos AC, Halperin JL, Kessler CM, Schulman S, Turpie AGG, et al. Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model. Blood. 2011;117:2089\u201392.","journal-title":"Blood"},{"key":"1063_CR7","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1093\/annonc\/mds168","volume":"23","author":"EL Trimble","year":"2012","unstructured":"Trimble EL, Ledermann J, Law K, Miyata T, Imamura CK, Nam B-H, et al. International models of investigator-initiated trials: implications for Japan. Ann Oncol. 2012;23:3151\u20135.","journal-title":"Ann Oncol"},{"key":"1063_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148455","volume":"11","author":"T Ito","year":"2016","unstructured":"Ito T. Differences in investigator-initiated trials between Japan and other countries: analyses of clinical trials sponsored by academia and government in the Clinicaltrials.gov registry and in the three Japanese registries. PLoS ONE. 2016;11:e0148455.","journal-title":"PLoS ONE"},{"key":"1063_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1297\/cpe.29.1","volume":"29","author":"H Saitou","year":"2020","unstructured":"Saitou H, Nakatani D, Myoui A, Kubota T, Ozono K. Pediatric drug development in Japan: current issues and perspectives. Clin Pediatr Endocrinol. 2020;29:1\u20137.","journal-title":"Clin Pediatr Endocrinol"},{"key":"1063_CR10","doi-asserted-by":"publisher","first-page":"1069933","DOI":"10.3389\/fmed.2022.1069933","volume":"9","author":"J-M Hoffmann","year":"2022","unstructured":"Hoffmann J-M, Grossmann R, Widmann A. Academic clinical trials: Publication of study results on an international registry-We can do better! Front Med (Lausanne). 2022;9:1069933.","journal-title":"Front Med (Lausanne)"},{"key":"1063_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037375","volume":"103","author":"L Huang","year":"2024","unstructured":"Huang L, Shi F, Hu D, Kang D. Analysis of research topics and trends in investigator-initiated research\/trials (IIRs\/IITs): a topic modeling study. Medicine (Baltimore). 2024;103:e37375.","journal-title":"Medicine (Baltimore)"},{"key":"1063_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103755","volume":"28","author":"K Enya","year":"2023","unstructured":"Enya K, Lim Y, Sengoku S, Kodama K. Increasing orphan drug loss in Japan: Trends and R&D strategy for rare diseases. Drug Discov Today. 2023;28:103755.","journal-title":"Drug Discov Today"},{"key":"1063_CR13","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/cpt.70001","volume":"119","author":"M Kobayashi","year":"2026","unstructured":"Kobayashi M, Narukawa M. Drug loss in Japan: a comparative analysis with Europe for new drugs developed by emerging biopharma companies. Clin Pharmacol Ther. 2026;119:1249\u201356.","journal-title":"Clin Pharmacol Ther"},{"key":"1063_CR14","first-page":"1","volume":"2026","author":"K Nakai","year":"2026","unstructured":"Nakai K. Japan\u2019s pharmaceutical regulatory reform to overcome drug loss issue. Ther Innov Regul Sci. 2026;2026:1\u20135.","journal-title":"Ther Innov Regul Sci."},{"key":"1063_CR15","unstructured":"Ministry of Health, Labour and Welfare. Report of the expert panel on comprehensive measures to ensure the rapid and stable supply of pharmaceuticals [Internet]; 2023 [cited 2026 Jul 28]. https:\/\/www.mhlw.go.jp\/content\/10807000\/001215514.pdf. Japanese."},{"key":"1063_CR16","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/cas.13223","volume":"108","author":"S Kondo","year":"2017","unstructured":"Kondo S, Hosoi H, Itahashi K, Hashimoto J. Quality evaluation of investigator-initiated trials using post-approval cancer drugs in Japan. Cancer Sci. 2017;108:995\u20139.","journal-title":"Cancer Sci"},{"key":"1063_CR17","unstructured":"Japan Consortium of Clinical Research Core Hospitals [Internet]. [cited 2026 Jul 28]. https:\/\/j-ccrc.net\/en\/about\/"},{"key":"1063_CR18","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.clinthera.2018.10.010","volume":"40","author":"N Tsuruya","year":"2018","unstructured":"Tsuruya N, Kawashima T, Shiozuka M, Nakanishi Y, Sugiyama D. Academia\u2013industry cooperation in the medical field: matching opportunities in Japan. Clin Ther. 2018;40:1807\u201312.","journal-title":"Clin Ther"},{"key":"1063_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/jjco\/hyaa028","volume":"50","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Shibata T. Regulatory changes after the enforcement of the new Clinical Trials Act in Japan. Jpn J Clin Oncol. 2020;50:399\u2013404.","journal-title":"Jpn J Clin Oncol"},{"key":"1063_CR20","unstructured":"Ministry of Health, Labour and Welfare. Overview of the designation system for orphan drugs, orphan medical devices, and orphan regenerative medical products [Internet]. [cited 2026 Jul 28]. https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000068484.html. Japanese."},{"key":"1063_CR21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s43441-022-00404-1","volume":"56","author":"Y Kubota","year":"2022","unstructured":"Kubota Y, Narukawa M. Randomized controlled trial data for new drug application for rare diseases in Japan. Ther Innov Regul Sci. 2022;56:659\u201366.","journal-title":"Ther Innov Regul Sci"},{"key":"1063_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02702-9","volume":"18","author":"Y Kubota","year":"2023","unstructured":"Kubota Y, Narukawa M. Randomized controlled trial data for successful new drug application for rare diseases in the United States. Orphanet J Rare Dis. 2023;18:89.","journal-title":"Orphanet J Rare Dis"},{"key":"1063_CR23","unstructured":"PMDA Pharmaceuticals Information Search [Internet]. [cited 2026 Jul 28]. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuSearch\/. Japanese."},{"key":"1063_CR24","unstructured":"MHLW Pharmaceutical Affairs Council (Pharmaceuticals Subcommittee I) [Internet]. [cited 2026 Jul 28]. Japanese."},{"key":"1063_CR25","unstructured":"MHLW Pharmaceutical Affairs Council (Pharmaceuticals Subcommittee II) [Internet]. [cited 2026 Jul 28]. https:\/\/www.mhlw.go.jp\/stf\/shingi-yakuji_39204.html. Japanese."},{"key":"1063_CR26","unstructured":"Asada R, Shibukawa K. Current Status of Orphan Drug Designation Requirements in Japan: A Study Based on a Survey of Pharmaceutical Companies [Internet]. [cited 2026 Jul 28]. Tokyo: Research Paper, Japan Pharmaceutical Manufacturers Association, Institute for International Health Economics and Policy; 2017. Report No.70. Japanese https:\/\/www.jpma.or.jp\/opir\/research\/rs_070\/pb1snq0000001299-att\/pdf_article_070_01.pdf"},{"key":"1063_CR27","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"1063_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70237","volume":"18","author":"L Frumkin","year":"2025","unstructured":"Frumkin L. Protocol development for investigator-sponsored clinical studies. Clin Transl Sci. 2025;18:e70237.","journal-title":"Clin Transl Sci"},{"key":"1063_CR29","unstructured":"Australian Clinical Trials Alliance. Economic evaluation of investigator-initiated clinical trials conducted by networks [Internet]. [cited 2026 Jul 28]. Sydney: Australian Commission on Safety and Quality in Health Care; 2017. https:\/\/www.safetyandquality.gov.au\/sites\/default\/files\/resources\/attachments\/Economic-evaluation-of-investigator-initiated-clinical-trials-conducted-by-networks.pdf."},{"key":"1063_CR30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.4103\/picr.PICR_106_18","volume":"9","author":"M Konwar","year":"2018","unstructured":"Konwar M, Bose D, Gogtay NJ, Thatte UM. Investigator-initiated studies: challenges and solutions. Perspect Clin Res. 2018;9:179\u201383.","journal-title":"Perspect Clin Res"},{"key":"1063_CR31","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.cmi.2015.07.004","volume":"21","author":"P-F Laterre","year":"2015","unstructured":"Laterre P-F, Fran\u00e7ois B. Strengths and limitations of industry vs. academic randomized controlled trials. Clin Microbiol Infect. 2015;21:906\u20139.","journal-title":"Clin Microbiol Infect"},{"key":"1063_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3790-9","volume":"20","author":"T Dombernowsky","year":"2019","unstructured":"Dombernowsky T, Haedersdal M, Lassen U, Thomsen SF. Criteria for site selection in industry-sponsored clinical trials: a survey among decision-makers in biopharmaceutical companies and clinical research organizations. Trials. 2019;20:708.","journal-title":"Trials"},{"key":"1063_CR33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nbt.2786","volume":"32","author":"M Hay","year":"2014","unstructured":"Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32:40\u201351.","journal-title":"Nat Biotechnol"},{"key":"1063_CR34","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/cts.12980","volume":"14","author":"S Yamaguchi","year":"2021","unstructured":"Yamaguchi S, Kaneko M, Narukawa M. Approval success rates of drug candidates based on target, action, modality, application, and their combinations. Clin Transl Sci. 2021;14:1113\u201322.","journal-title":"Clin Transl Sci"},{"key":"1063_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1858688","volume":"17","author":"E De Paola","year":"2026","unstructured":"De Paola E, Dri DA, Verrelli NM, Galliccia F. A decade of clinical trials in Italy (2016-2025): trends, regulatory transformation and biotechnological evolution. Front Pharmacol. 2026;17:1858688.","journal-title":"Front Pharmacol"},{"key":"1063_CR36","unstructured":"Pharmaceuticals and Medical Devices Agency. Trends in the Number of Notifications of Clinical Trial Plans for Drugs in Japan [Internet]. [cited 2026 July 28]. https:\/\/www.pmda.go.jp\/files\/000281023.pdf. Japanese."},{"key":"1063_CR37","unstructured":"Duke Clinical Research Institute [Internet]. [cited 2026 Jul 28]. https:\/\/dcri.org\/."},{"key":"1063_CR38","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/978-3-319-67144-4_20","volume":"1031","author":"CM Cutillo","year":"2017","unstructured":"Cutillo CM, Austin CP, Groft SC. A global approach to rare diseases research and orphan products development: the International Rare Diseases Research Consortium (IRDiRC). Adv Exp Med Biol. 2017;1031:349\u201369.","journal-title":"Adv Exp Med Biol"},{"key":"1063_CR39","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/cts.12965","volume":"14","author":"T Hata","year":"2021","unstructured":"Hata T, Nakamura K, Yonemori K, Noguchi E, Watanabe M, Sohn J, et al. Regulatory and operational challenges in conducting Asian international academic trial for expanding the indications of cancer drugs. Clin Transl Sci. 2021;14:1015\u201325.","journal-title":"Clin Transl Sci"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01063-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-01063-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01063-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:41:43Z","timestamp":1792813303000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-01063-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":39,"alternative-id":["1063"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-01063-2","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"3 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors have no conflicts of interest directly relevant to this research.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}